Lakeshore Biopharma (LSB) Competitors $1.10 -0.05 (-4.35%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$1.10 0.00 (0.00%) As of 05/21/2025 05:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LSB vs. MRSN, IMRX, IRD, IPSC, CNTB, RNTX, KPTI, PRLD, QNCX, and PLURShould you be buying Lakeshore Biopharma stock or one of its competitors? The main competitors of Lakeshore Biopharma include Mersana Therapeutics (MRSN), Immuneering (IMRX), Opus Genetics (IRD), Century Therapeutics (IPSC), Connect Biopharma (CNTB), Rein Therapeutics (RNTX), Karyopharm Therapeutics (KPTI), Prelude Therapeutics (PRLD), Quince Therapeutics (QNCX), and Pluri (PLUR). These companies are all part of the "pharmaceutical products" industry. Lakeshore Biopharma vs. Mersana Therapeutics Immuneering Opus Genetics Century Therapeutics Connect Biopharma Rein Therapeutics Karyopharm Therapeutics Prelude Therapeutics Quince Therapeutics Pluri Mersana Therapeutics (NASDAQ:MRSN) and Lakeshore Biopharma (NASDAQ:LSB) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, media sentiment, community ranking, risk, institutional ownership and earnings. Do institutionals & insiders hold more shares of MRSN or LSB? 93.9% of Mersana Therapeutics shares are held by institutional investors. Comparatively, 52.6% of Lakeshore Biopharma shares are held by institutional investors. 13.0% of Mersana Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has more risk & volatility, MRSN or LSB? Mersana Therapeutics has a beta of 1.32, suggesting that its stock price is 32% more volatile than the S&P 500. Comparatively, Lakeshore Biopharma has a beta of 0.64, suggesting that its stock price is 36% less volatile than the S&P 500. Which has stronger earnings & valuation, MRSN or LSB? Lakeshore Biopharma has higher revenue and earnings than Mersana Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMersana Therapeutics$40.50M1.09-$171.67M-$0.59-0.60Lakeshore Biopharma$672.27M0.02-$61.09MN/AN/A Does the media prefer MRSN or LSB? In the previous week, Mersana Therapeutics had 24 more articles in the media than Lakeshore Biopharma. MarketBeat recorded 24 mentions for Mersana Therapeutics and 0 mentions for Lakeshore Biopharma. Mersana Therapeutics' average media sentiment score of 0.42 beat Lakeshore Biopharma's score of 0.00 indicating that Mersana Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Mersana Therapeutics Neutral Lakeshore Biopharma Neutral Does the MarketBeat Community believe in MRSN or LSB? Mersana Therapeutics received 256 more outperform votes than Lakeshore Biopharma when rated by MarketBeat users. CompanyUnderperformOutperformMersana TherapeuticsOutperform Votes25666.49% Underperform Votes12933.51% Lakeshore BiopharmaN/AN/A Is MRSN or LSB more profitable? Lakeshore Biopharma has a net margin of 0.00% compared to Mersana Therapeutics' net margin of -214.20%. Lakeshore Biopharma's return on equity of 0.00% beat Mersana Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Mersana Therapeutics-214.20% -401.37% -38.61% Lakeshore Biopharma N/A N/A N/A Do analysts rate MRSN or LSB? Mersana Therapeutics currently has a consensus target price of $5.20, indicating a potential upside of 1,371.84%. Given Mersana Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Mersana Therapeutics is more favorable than Lakeshore Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mersana Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00Lakeshore Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryMersana Therapeutics beats Lakeshore Biopharma on 11 of the 16 factors compared between the two stocks. Get Lakeshore Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for LSB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LSB vs. The Competition Export to ExcelMetricLakeshore BiopharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.24M$6.52B$5.37B$8.39BDividend YieldN/A2.65%5.22%4.10%P/E RatioN/A8.9226.8419.71Price / Sales0.02253.80392.34117.39Price / CashN/A65.8538.2534.62Price / Book0.126.466.794.50Net Income-$61.09M$143.98M$3.23B$248.18M7 Day Performance2.13%2.03%1.53%0.20%1 Month Performance-18.82%4.11%10.05%12.37%1 Year PerformanceN/A-2.87%16.71%7.04% Lakeshore Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LSBLakeshore Biopharma0.5733 of 5 stars$1.10-4.3%N/AN/A$10.24M$672.27M0.00773Positive NewsGap UpMRSNMersana Therapeutics3.7886 of 5 stars$0.35-3.6%$3.67+954.5%-86.5%$43.33M$40.50M-0.57150Earnings ReportAnalyst RevisionGap DownIMRXImmuneering2.1353 of 5 stars$1.20+0.8%$15.33+1,177.8%-3.9%$43.18M$320,000.00-0.6160IRDOpus Genetics2.0295 of 5 stars$0.95-0.3%$7.33+674.4%N/A$43.07M$10.99M-0.8714Earnings ReportIPSCCentury Therapeutics2.4852 of 5 stars$0.50-5.1%$4.40+783.2%-80.5%$42.92M$6.59M-0.27170Earnings ReportAnalyst RevisionGap UpCNTBConnect Biopharma3.2682 of 5 stars$0.78-3.4%$8.00+932.3%-54.0%$42.90M$26.03M0.00110Earnings ReportRNTXRein TherapeuticsN/A$1.95+8.1%N/AN/A$42.77MN/A-0.629Earnings ReportGap DownKPTIKaryopharm Therapeutics3.8392 of 5 stars$4.97-19.2%$45.60+817.5%-72.0%$42.59M$145.24M-4.87380Gap DownHigh Trading VolumePRLDPrelude Therapeutics3.0327 of 5 stars$0.97+9.3%$4.00+314.5%-77.7%$42.08M$7M-0.54120Positive NewsQNCXQuince Therapeutics2.908 of 5 stars$0.94-8.7%$8.00+751.1%+19.8%$41.48MN/A-0.7660PLURPluri0.4083 of 5 stars$5.24-2.4%N/A-25.8%$40.73M$678,000.00-0.94150 Related Companies and Tools Related Companies Mersana Therapeutics Competitors Immuneering Competitors Opus Genetics Competitors Century Therapeutics Competitors Connect Biopharma Competitors Rein Therapeutics Competitors Karyopharm Therapeutics Competitors Prelude Therapeutics Competitors Quince Therapeutics Competitors Pluri Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LSB) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersWarning: Prepare to Be Shocked by These PayoutsThere's a strategy out there paying up to 70% on tech stocks like Amazon, Tesla, and Microsoft—stocks that don...Investors Alley | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredTrump’s treachery I think Trump’s Treasury Secretary is destroying the stock market on purpose. And no one on Wall Street see...Porter & Company | Sponsored🚨 Nvidia Just Inked a $7B AI Deal—This Could Change EverythingOn Wednesday, Nvidia stock surged—again. Why? Because Saudi Arabia just announced a multi-billion-dollar AI...Timothy Sykes | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lakeshore Biopharma Co., Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lakeshore Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy LSB Stock Free LSB Stock Alerts